Successful salvage with high-dose sequential chemotherapy coupled with in vivo purging and autologous stem cell transplantation in 2 patients with primary refractory mantle cell lymphoma presenting in the leukemic phase

International Journal of Hematology

Volumn 81, Issue 2, 2005, Pages 155-158

  Oyan, Basak ^a   Koc, Yener ^a   Kansu, Emin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Autologous transplantation; High dose therapy; Mantle cell lymphoma; Rituximab; Salvage

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CD23 ANTIGEN; CD34 ANTIGEN; CD5 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IDARUBICIN; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VANCOMYCIN; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISKITIS; FEBRILE NEUTROPENIA; FLOW CYTOMETRY; HERPES SIMPLEX; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LYMPH NODE BIOPSY; MALE; MANTLE CELL LYMPHOMA; PROGNOSIS; REMISSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW PURGING; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 13944262439     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.E0303     Document Type: Article

References (19)

1. Armitage JO, Weisenburger DD. New approaches to classifying non-Hodgkin's lymphoma: clinical features of the major subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780-2795.
2. Weisenburger DD, Armitage JO. Mantle cell lymphoma: an entity comes of age. Blood. 1996;87:4483-4494.
3. Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective compared analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol. 1998;16:1922-1930.
4. Mangel J, Buckstein R, Imrie K, et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol. 2002;29(suppl 2):56-69.
5. Vose JM, Bierman PF, Weisenburger DD, et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant. 2000;6:640-645.
6. Rummel MJ, Chow KU, Jager E, et al. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. Ann Oncol. 1999;10:115-117.
7. Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998; 16:13-18.
8. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998;16:3803-3809.
9. Vanderberghe E, Ruiz de Elvira C, Isaacson P, et al. Does transplantation improve outcome in mantle cell lymphoma? A study from the EBMT [abstract]. Blood. 2000;96:482a.
10. Freedman AS, Gribben JG, Nadler LM. High dose therapy and autologous stem cell transplantation in follicular non-Hodgkin's lymphoma. Leuk Lymphoma. 1998;28:219-230.
11. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood. 2000;96:864-869.
12. Lazzarino M, Arcaini L, Bernasconi P, et al. A sequence of immuno-chemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol. 2002;116:229-235.
13. Molina A, Nademanee A, O'Donnel MR, et al. Autologous and allogeneic stem cell transplantation for poor-risk mantle cell lymphoma: the City of Hope experience [abstract]. Blood. 1998;92: 459a.
14. + enriched peripheral blood stem cell transplantation [abstract]. Blood. 2000;96:482a.
15. Corradini P, Astolfi M, Cherasco C, et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood. 1997;89: 724-731.
16. Zinzani PL, Magagnoli M, Moretti L, et al. Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients. Haematologica. 1999;84:1002-1006.
17. Zinzani PL, Bebdandi M, Gherlinzoni F, Merla E, Gozzetti A, Tura S. FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphoma. Haematologica. 1996;81:168-171.
18. Dreger P, Martin S, Kuse R, et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J. 2000;1:87-94.
19. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89:2067-2078.